Law

As lawyers, we have to get client approval before we can discuss their litigation substantively.  Here are a couple just-in decisions where we’re doing that, but that are important enough our readers would want to know about them right away.  In re Incretin-Based Therapies Products Liability Litigation, slip op. (S.D. Cal. Nov. 9, 2015) (win on Levine “clear evidence” prescription drug preemption); In re Testosterone Replacement Therapy Products Liability Litigation, slip op. (N.D. Ill. Nov. 9, 2015) (win on generic drug preemption involving reference listed drugs).  Assuming we get approval to discuss these decisions later, we will.


--
Posted By Bexis to Drug and Device Law at 11/10/2015 10:47:00 AM

--
You received this message because you are subscribed to the Google Groups "Drug and Device Law" group.
To post to this group, send email to drug-and-device-law@googlegroups.com
To unsubscribe from this group, send email to drug-and-device-law-unsubscribe@googlegroups.com
For more options, visit this group at http://groups.google.com/group/drug-and-device-law?hl=en
---
You received this message because you are subscribed to the Google Groups "Drug and Device Law" group.
To unsubscribe from this group and stop receiving emails from it, send an email to drug-and-device-law+unsubscribe@googlegroups.com.
For more options, visit https://groups.google.com/d/optout.